Nationwide survey on HER2 and PD-L1 testing practices in gastric cancer across Japan
Gastric Cancer · 2025-03 · 28 (2) · 294-300
DOI: 10.1007/s10120-024-01571-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastric Cancer, online erschienen am 10.12.2024. Verfasst von Hiroyuki Abe und 3 weiteren Autor:innen. Beteiligte Einrichtung: Japanese Gastric Cancer Association, Kyoto, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases, B7-H1 Antigen, Biomarkers, Tumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University of Tokyo.
Abstract (Originalsprache)
Background
Since HER2 and PD-L1 testing are key to selecting drugs for first-line treatments in advanced gastric cancer, evaluating differences in these tests among institutions is necessary to standardize treatment.
Methods
A questionnaire survey was conducted targeting institutions certified by the Japanese Gastric Cancer Association.
Results
Responses were obtained from 155 institutions. Most institutions performed HER2 testing in-house, while PD-L1 tests were largely outsourced. HER2 scores and PD-L1 CPS rates showed greater variability across institutions than anticipated. In the pre-analytic phase, 10% neutral buffered formalin was commonly used, with fixation practices generally following guidelines. Overall, the impact of fixation-related factors was limited, but in surgical specimens, longer fixation was associated with a higher proportion of score 0/1+ and a lower proportion of score 3+. When examining HER2 scores by institution, if a particular score had a high (or low) frequency in biopsy, the same trend was also seen in surgical specimens.
Conclusions
These findings suggest that not only factors related to specimen preparation, but also biases in evaluation criteria among pathologists may contribute to the significant variability among institutions. Standardization of pre- and post-analytic phases, coupled with appropriate training, is essential to achieve consistent gastric cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Japanese Gastric Cancer Association, Kyoto, Japan.
- Department of Pathology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
- Department of Genetic Medicine and Services, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Pathology, Shiga University of Medical Science, Otsu, Japan.
- Japanese Gastric Cancer Association, Kyoto, Japan. usikut@g.ecc.u-tokyo.ac.jp.
- Department of Pathology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan. usikut@g.ecc.u-tokyo.ac.jp.
ORCID-Profile: Tetsuo Ushiku
Förderung
- The University of Tokyo
Zitieren
APA
Abe, H., Kuwata, T., Kushima, R., & Ushiku, T. (2025). Nationwide survey on HER2 and PD-L1 testing practices in gastric cancer across Japan. Gastric Cancer, 28(2), 294-300. https://doi.org/10.1007/s10120-024-01571-w
Vancouver
Abe H, Kuwata T, Kushima R, Ushiku T. Nationwide survey on HER2 and PD-L1 testing practices in gastric cancer across Japan. Gastric Cancer. 2025;28(2):294-300. doi:10.1007/s10120-024-01571-w
BibTeX
@article{Abe2025,
author = {Abe, Hiroyuki and Kuwata, Takeshi and Kushima, Ryoji and Ushiku, Tetsuo},
title = {Nationwide survey on HER2 and PD-L1 testing practices in gastric cancer across Japan},
journal = {Gastric Cancer},
year = {2025},
volume = {28},
number = {2},
pages = {294--300},
doi = {10.1007/s10120-024-01571-w}
}
EUVIMED